Globalpharma's Strategic MoUs Boost UAE Pharma Hub
Globalpharma, a subsidiary of Dubai Investments, signs key MoUs to enhance UAE's pharmaceutical sector.
Summary
Globalpharma has signed four strategic MoUs to strengthen the UAE's pharmaceutical industry, highlighting its role as a regional hub for innovation.
In a significant move to bolster the UAE's pharmaceutical landscape, Globalpharma, wholly owned by Dubai Investments PJSC, has inked four strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. These agreements are pivotal in reinforcing the UAE's position as a regional hub for pharmaceutical innovation, localization, and advanced healthcare manufacturing.
The MoUs were signed with international players PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada). These collaborations focus on critical areas such as technology transfer, product licensing, supply, and local manufacturing, all aligned with the UAE's industrial strategy to bolster domestic production and reduce reliance on imports.
His Excellency Dr. Thani Al Zeyoudi, UAE Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment, emphasized that these strategic collaborations embody the core goals of the 'Make it in the Emirates' initiative — empowering local industry, accelerating innovation, and enhancing the country's position as a global hub for high-quality, future-ready healthcare solutions.
Among the notable agreements, PharmaPrimes Laboratories will establish advanced local capabilities for batch release and analysis of biosimilar drugs in the UAE, enhancing the competitiveness of the pharmaceutical sector in the GCC region. Meanwhile, Nerhadou International will introduce a portfolio of innovative nutraceutical and over-the-counter (OTC) products tailored to regional health needs, promoting preventive care and healthier lifestyles.
Dubai Investments' commitment to advancing the UAE's industrial capabilities and promoting knowledge transfer is evident through these strategic partnerships. Mohammed Saeed Al Raqbani, General Manager of Dubai Investments Industries and Board Director at Globalpharma, highlighted the company's vision to build a resilient pharmaceutical ecosystem that supports regional health security and innovation-driven growth.
From an investment perspective, these developments present a promising outlook for Dubai Investments PJSC. The strategic MoUs not only strengthen Globalpharma's market position but also enhance the UAE's role as a key player in the global pharmaceutical industry. Investors should consider this as a positive indicator of the company's growth trajectory and its potential to deliver sustainable financial returns.
Given the strategic nature of these partnerships and the alignment with national industrial goals, the recommendation for investors is to buy Dubai Investments PJSC shares. The company's proactive approach in securing these MoUs positions it well for future growth and value creation.
Source
Summary
Globalpharma, a leading pharmaceutical manufacturer in the UAE, has signed four strategic Memorandums of Understanding (MoUs) during the Make it in the Emirates Forum 2025. These agreements aim to strengthen the UAE's position as a hub for pharmaceutical innovation and advanced healthcare manufacturing. The MoUs involve collaborations with PharmaPrimes Laboratories (Jordan), Nerhadou International (Egypt), Aora Health (Spain), and BioSyent Pharma Inc. (Canada), focusing on technology transfer, product licensing, supply, and local manufacturing. These partnerships align with the UAE's industrial strategy to boost domestic production, reduce import dependence, and enhance access to next-generation healthcare solutions. The agreements reflect the UAE's commitment to empowering local industry, accelerating innovation, and establishing the country as a global hub for high-quality healthcare solutions. Specific collaborations include PharmaPrimes Laboratories working on biosimilar drug capabilities in the UAE and Nerhadou International introducing a range of nutraceutical and OTC products tailored to regional health needs.
